Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | G6PD | P11413 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245039 | 0.71 | LMNA (0.46) | ALDH1A1LMNAGLAKDM4EGAA | |
| SCHEMBL3988944 | 0.71 | LMNA (0.39) | ALDH1A1LMNAGLANOTUMTDP1 | |
| SCHEMBL967912 | 0.69 | ALDH1A1 (0.44) | ALDH1A1LMNAGLAKDM4EGAA | |
| SCHEMBL28204860 | 0.69 | CYP2A6 (0.39) | ALDH1A1LMNAGLAKDM4EGAA | |
| SCHEMBL4205737 | 0.68 | LMNA (0.37) | ALDH1A1LMNAGLAKDM4EGAA | |
| Bromide SCHEMBL28839161 | 0.68 | CYP2A6 (0.38) | ALDH1A1LMNAGLAKDM4EGAA | |
| SCHEMBL17895476 | 0.68 | ALDH1A1 (0.42) | ALDH1A1LMNAGLAKDM4EGAA | |
| SCHEMBL5535789 | 0.68 | NOTUM (0.40) | ALDH1A1LMNAKDM4EGAAMAPT | |
| SCHEMBL12402363 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNAKDM4EGAAMAPT | |
| SCHEMBL27991917 | 0.68 | ADORA2A (0.38) | ALDH1A1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113264928-A | Dihydropyrazole thiazole derivative and preparation method and application thereof | 合肥工业大学 | 2021-08-17 | — | — | CN | claimed |
| US-20190134140-A1 | ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS | BURCH LAURANELL HARRISON (US) | 2019-05-09 | — | — | US | claimed |
| EP-1819721-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | Plant Bioscience Limited (GB) | 2007-08-22 | — | — | EP | claimed |
| WO-2006054102-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | PLANT BIOSCIENCE LIMITED (GB) | 2006-05-26 | — | — | WO | claimed |
| EP-0968179-B1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2002-09-25 | — | — | EP | claimed |
| US-4766138-A | Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives | ZAMBON S.P.A. (IT) | 1988-08-23 | — | — | US | claimed |
| EP-0191045-A1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES. | ZAMBON SPA (IT) | 1986-08-20 | — | — | EP | claimed |
| WO-1986000899-A1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES | ZAMBON S.P.A. (IT) | 1986-02-13 | — | — | WO | claimed |
| EP-3976605-B1 | METHODS FOR MAKING THIAZOLYLPYRAZOLE CARBOXYLIC ACIDS AND INTERMEDIATES THEREFOR | BANTAM PHARMACEUTICAL LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12378234-B2 | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative | BANTAM PHARMACEUTICAL, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12378234-B2 | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative | BANTAM PHARMACEUTICAL, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12358905-B2 | Methods for making thiazolypyrazole carboxylic acids and intermediates therefor | Bantam Pharamceutical, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12358905-B2 | Methods for making thiazolypyrazole carboxylic acids and intermediates therefor | Bantam Pharamceutical, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250109129-A1 | ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS | MIRALOGX LLC | 2025-04-03 | — | — | US | disclosed |
| US-20020049215-A1 | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | AGOURON PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-20020049215-A1 | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | AGOURON PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-20020049215-A1 | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | AGOURON PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2002012250-A2 | PYRAZOLE-THIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012250-A2 | PYRAZOLE-THIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-4113717-A | Quaternized azo dyestuffs | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049215-A1 | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | CDK4, CCNK, CDK2 | ALDH1A1 2325/4885LMNA 3010/4885GLA 1791/4885 |
| US-12358905-B2 | Methods for making thiazolypyrazole carboxylic acids and intermediates therefor | ABAT, WEE1, HADHB | ALDH1A1 301/4885LMNA 4092/4885GLA 3221/4885 |
| US-20250109129-A1 | ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS | CLPP, NISCH, MRPL21 | ALDH1A1 2739/4885LMNA 4154/4885GLA 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.